Welcome to our dedicated page for AB Corporate Bond ETF news (Ticker: EYEG), a resource for investors and traders seeking the latest updates and insights on AB Corporate Bond ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AB Corporate Bond ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AB Corporate Bond ETF's position in the market.
EyeGate Pharmaceuticals (EYEG) reported its Q1 2021 financial results, highlighting progress in its clinical development programs for PP-001 and OBG. The company plans to initiate clinical studies in Q3 and Q4 2021, including proof-of-concept trials in Austria for dry eye disease and persistent epithelial defects. R&D expenses increased to $1.280 million, while cash and cash equivalents rose to $6.610 million, significantly boosted by a recent private placement. The company is focused on advancing its pipeline targeting inflammatory eye diseases.
EyeGate Pharmaceuticals (NASDAQ: EYEG) has appointed Kenneth Gayron and Aron Shapiro to its Board of Directors, replacing Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D. Gayron, a seasoned CFO with expertise in strategic growth, will chair the Audit Committee, while Shapiro brings extensive experience in clinical-regulatory strategy. Their appointments aim to enhance EyeGate's operational capabilities as it advances its clinical pipeline, including the development of its lead product, PP-001, designed for treating inflammatory and immune diseases.
EyeGate Pharmaceuticals (NASDAQ: EYEG) announced its financial results for 2020, revealing revenues of $0.012 million, a drastic decline from $2.686 million in 2019 due to terminated license agreements. The company's acquisition of Panoptes in December 2020 enhances its product pipeline, introducing PP-001, a promising clinical-stage asset for ocular and systemic diseases. Research and development expenses decreased to $3.566 million, while general and administrative expenses rose to $4.659 million. Cash and cash equivalents fell to $1.186 million, largely due to operational outflows and the acquisition.
EyeGate Pharmaceuticals announced a significant management transition effective February 1, 2021. Franz Obermayr, Ph.D., former EVP Clinical Development, has been appointed as Acting Chief Executive Officer, taking the lead during EyeGate's expansion into new therapeutic areas beyond ophthalmology. Stephen From has been elevated to Executive Chairman. This transition follows EyeGate's acquisition of Panoptes Pharma, enhancing their pipeline with the promising drug PP-001. The leadership change aims to leverage Obermayr's expertise and further develop EyeGate's innovative treatments for inflammatory conditions.
EyeGate Pharmaceuticals (NASDAQ: EYEG) announced a private placement agreement with Armistice Capital, LLC, resulting in approximately $8.0 million in gross proceeds. Under the deal, EyeGate will issue 1,531,101 shares of common stock and warrants to purchase an equivalent number of shares at a combined price of $5.225 per share and warrant. The proceeds will be allocated for clinical trials, working capital, and other corporate purposes. The closing is anticipated on January 6, 2021, pending customary conditions.
EyeGate Pharmaceuticals (NASDAQ: EYEG) announced the acquisition of Panoptes Pharma, enhancing its pipeline with PP-001, a novel DHODH inhibitor designed for treating severe eye diseases.PP-001 presents a best-in-class potential with optimized specificity and picomolar potency, backed by promising clinical data in various formulations. The acquisition also strengthens EyeGate's leadership with Panoptes co-founders joining the team. The deal involves an initial payment of $4 million and additional performance-based earn-outs of up to $9.5 million, contingent on clinical milestones.
EyeGate Pharmaceuticals (NASDAQ: EYEG) announced financial results for Q3 2020, showing a significant decrease in Research and Development Expenses of $0.986 million compared to $2.406 million in Q3 2019. General and Administrative Expenses also saw a slight drop to $1.021 million. Cash and cash equivalents decreased to $2.931 million, influenced by operational costs, though partially offset by a $4.501 million stock offering. The company received positive FDA feedback for its MoxiGel product aimed at treating bacterial conjunctivitis, demonstrating a clear path forward.
WALTHAM, MA / ACCESSWIRE / September 8, 2020 / EyeGate Pharmaceuticals (NASDAQ:EYEG) announced that CEO Stephen From will present at the H.C. Wainwright 22nd Annual Global Investment Conference from September 14-16, 2020.
Presentation Details:
- Date: September 15, 2020
- Time: 4:00-4:20pm EST
- Webcast: Live Audio Webcast
EyeGate focuses on eye disorder treatments, with its lead product Ocular Bandage Gel aimed at healing corneal defects.
EyeGate Pharmaceuticals (NASDAQ:EYEG) announced receiving positive feedback from the FDA following its pre-IND meeting for MoxiGel, a treatment for bacterial conjunctivitis. This product merges EyeGate's Ocular Bandage Gel with an FDA-approved antibiotic. EyeGate plans to finalize pre-clinical work and submit an IND in the first half of 2021. The company focuses on developing products for eye disorders, with its lead product aimed at improving corneal integrity post-surgery.
EyeGate Pharmaceuticals (NASDAQ:EYEG) announced positive feedback from its pre-IND meeting with the FDA regarding the development of MoxiGel, a combination treatment for bacterial conjunctivitis. This product will merge EyeGate's Ocular Bandage Gel with an approved antibiotic. The company aims to complete pre-clinical work and submit an IND by the first half of 2021.
EyeGate's lead product, OBG, is designed to aid ocular surface healing, enhancing treatment for related conditions.
FAQ
What is the current stock price of AB Corporate Bond ETF (EYEG)?
